Login to Your Account

Generics and Teva position themselves for Copaxone win

By Mari Serebrov
Washington Editor

Tuesday, April 15, 2014
Hoping for a checkmate, generic drugmakers petitioned the Supreme Court Monday to either clear the board for a late May launch of generic versions of Copaxone or force Teva Pharmaceuticals USA Inc. to post a hefty bond to reimburse them for their losses if its final patent on the multiple sclerosis (MS) drug remains struck down on appeal.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription